A few studies have implicated CD4+ Th17 cells and their cytokines and downstream pathways in the pathogenesis of CNS autoimmunity in MS [42,55] and NMO [100,101], challenging the classical Th1/Th2 paradigm. This evidence concerns the gene CD4 and myeloid sarcoma.